Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

16. Kim D. A Benzenesulfonamide-based mitochondrial uncoupler induces endoplasmic reticulum stress and immunogenic cell death in epithelial ovarian cancer . Molecular Cancer Theraeputics. 2021; 21 : 2398-2409

17. Kim D. A Kidney-Targeted Nanoparticle to Augment Renal Lymphatic Density Decreases Blood Pressure in Hypertensive Mice . Pharmaceutics. 2021; 14 : 84

18. Kim D. pH-responsive Nanomedicine for Image-guided Drug Delivery . Pan Stanford Publishing. 2021

19. Kim D. Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin. Nature Biomedical Engineering. In Press; 5 : 983-997

20. Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Tumor-Targeting Liposomes with Transient Holes Allowing Intact Rituximab Internally. Biomacromolecules. 2020

Grants

1. Drug-Targeting ORP4 as a Precision Ovarian Cancer Target. DOD. Start Date: 2025. End Date: 2029.

2. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

3. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

4. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2026.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results